Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high
Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.
대표청구항▼
1. A transdermal delivery system, comprising: a pressure sensitive adhesive matrix comprising sufentanil in an amount above the saturation point of sufentanil in the matrix, wherein the matrix consists of both dissolved and undissolved sufentanil,a blend of high molecular weight polyisobutylene and
1. A transdermal delivery system, comprising: a pressure sensitive adhesive matrix comprising sufentanil in an amount above the saturation point of sufentanil in the matrix, wherein the matrix consists of both dissolved and undissolved sufentanil,a blend of high molecular weight polyisobutylene and low molecular weight polyisobutylene, the high molecular weight polyisobutylene having a viscosity average molecular weight of about 450,000 to 2,100,000, the low molecular weight polyisobutylene having a viscosity average molecular weight of about 1,000 to 450,000,polybutene, andsilicon dioxide;wherein the system provides a substantially zero order delivery rate of sufentanil over a single application administration period of at least about 48 hours; andwherein the system does not comprise a rate controlling membrane. 2. The transdermal delivery system of claim 1, wherein the system does not contain a permeation enhancer. 3. The transdermal delivery system of claim 1, wherein the sufentanil is present in the system in an amount of about 1 to about 20 weight percent relative to the total system. 4. The transdermal delivery system of claim 1, wherein the high molecular weight polyisobutylene has a viscosity average molecular weight of about 1,100,000. 5. The transdermal delivery system of claim 1, wherein the low molecular weight polyisobutylene has a viscosity average molecular weight of about 50,000 to 55,000. 6. The transdermal delivery system of claim 1, wherein the adhesive matrix has a drug releasing interface surface area of 40 cm2 or less. 7. The transdermal delivery system of claim 1, wherein the system comprises a reservoir having a volume of about 0.0025 to 0.154 ml. 8. The transdermal delivery system of claim 1, wherein the delivery rate at steady state is at least about 1 μg/hour. 9. The transdermal delivery system of claim 8, wherein the delivery rate at steady state is at least about 1.5 μg/hour. 10. The transdermal delivery system of claim 9, wherein the delivery rate at steady state is at least about 2 μg/hour. 11. The transdermal delivery system of claim 1, wherein net flux from the system through the skin is at least about 1 μg/cm2/hour. 12. The transdermal delivery system of claim 1, wherein the matrix has a solubility for sufentanil of about 1 wt % to about 2 wt %. 13. A transdermal delivery system, comprising: a pressure sensitive adhesive matrix comprising sufentanil in an amount above the saturation point of sufentanil in the matrix, wherein the matrix consists of both dissolved and undissolved sufentanil,a blend of high molecular weight polyisobutylene and low molecular weight polyisobutylene, the high molecular weight polyisobutylene having a viscosity average molecular weight of about 1,100,000, the low molecular weight polyisobutylene having a viscosity average molecular weight of about 50,000 to 55,000,polybutene, andsilicon dioxide;wherein the system does not comprise a rate controlling membrane. 14. The transdermal delivery system of claim 13, wherein the system provides a substantially zero order delivery rate of sufentanil over a single application administration period of at least about 48 hours. 15. The transdermal delivery system of claim 13, wherein the system does not contain a permeation enhancer. 16. The transdermal delivery system of claim 13, wherein the sufentanil is present in the system in an amount of about 1 to about 20 weight percent relative to the total system. 17. The transdermal delivery system of claim 13, wherein the adhesive matrix has a drug releasing interface surface area of 40 cm2 or less. 18. The transdermal delivery system of claim 13, wherein the system comprises a reservoir having a volume of about 0.0025 to 0.154 ml. 19. The transdermal delivery system of claim 13, wherein the system provides a delivery rate at steady state of at least about 1 μg/hour. 20. The transdermal delivery system of claim 13, wherein the system provides a delivery rate at steady state of at least about 1.5 μg/hour. 21. The transdermal delivery system of claim 13, wherein the system provides a delivery rate at steady state of at least about 2 μg/hour. 22. The transdermal delivery system of claim 13, wherein net flux from the system through the skin is at least about 1 μg/cm2/hour.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (135)
Lee Eun S. (Redwood City CA) Goetz Victor (Philadelphia PA), Abusable substance dosage form having reduced abuse potential.
Urquhart John (Palo Alto CA) Chandrasekaran Santosh Kumar (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Bandage for transdermally administering scopolamine to prevent nausea.
Mller Walter (Neuwied DEX) Czech Zbigniew (Koblenz DEX) Simon Gnter (Hillesheim DEX) Reinhard Joerg (Ehrenkirchen DEX), Basic active component-permeable pressure sensitive adhesive polymer material process of the production thereof and use.
Lee Eun Soo (Redwood City CA) Theeuwes Felix (Los Altos Hills CA) Wong S. L. Patrick (Hayward CA) Yum Su Il (Los Altos CA) Zaffaroni Alejandro (Atherton CA), Delayed onset transdermal delivery device.
Shah Kishore (Bridgewater NJ) Kydonieus Agis (Kendall Park NJ), Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate c.
Ebert Charles D. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT) Heiber Werner (Salt Lake City UT) Borsadia Suresh (Salt Lake City UT), Drug-containing adhesive composite transdermal delivery device.
Mahjour Majid (Netcong NJ) Mauser Bernadette E. (Lyndhurst NJ) Fawzi Mahdi B. (Flanders NJ), Fatty acids and their small chain esters as penetration enhancers in aqueous systems.
Kim Jung J. (Anyang-shi KRX) Lee Woo Y. (Anyang-shi KRX) Ahn Jong W. (Seoul KRX) Han Sang H. (Suwon-shi KRX), Medicinal adhesive for percutaneous administration.
Chandrasekaran Santosh Kumar (Palo Alto CA) Urquhart John (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Method and therapeutic system for providing chemotherapy transdermally.
Levy Gerhard (Williamsville NY) Southam Mary (Portola Valley CA) Powers Cramer Marilou S. (Redwood CA), Method of fentanly administration for postoperative pain relief.
Srinivasan Venkateshwaran ; David Fikstad ; Charles D. Ebert, Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions.
Tucker Mark J. (Round Steps ; High Street Stow-on-the-Wold ; Gloucester GL54 1DL GBX) Tucker Mark R. (P.O. Box 23530 Bahrain BHX), Occlusive body for administering a physiologically active substance.
Wolter Karin (Altwieder Str. 46 D-5451 Melsbach DEX) Herrmann Fritz (Rheinheldestr. 12c D-5450 Neuwied 12 DEX) Hoffmann Hans R. (Burghofstrasse 113 D-5450 Neuwied 12 DEX) Simon Gnter (Tulpenweg 1 D-5, Planar therapeutic system, process for its production and utilization.
Chen Tung-Fen ; Chiang Chia-Ming ; Jona Janan ; Joshi Priti ; Ramdas Asha, Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufactu.
Lothar W. Kleiner ; Robert M. Gale ; Randall G. Berggren ; Gilbert T. Tong ; Guohua Chen ; Keith E. Dionne ; Paul R. Houston, Rate controlling membranes for controlled drug delivery devices.
Pfister William R. (Bay City MI) Wilson Jeniffer M. (Saginaw MI), Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices.
Sweet Randall P. (Midland MI) Durfee Loren D. (Midland MI) Ulman Katherine L. (Sanford MI), Silicone pressure sensitive adhesive containing alkylmethylsiloxane wax and related methods and devices.
Burkoth Terry L.,GB2 ; Taskovich Lina T. ; Beste Russell D. ; Gale Robert M. ; Lee Eun Soo ; Hamlin Richard D. ; Yum Su LL, Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate.
Lee Eun Soo (Redwood City CA) Nedberge Diane E. (Los Altos CA) Yum Su Il (Los Altos CA), Skin permeation enhancer compositions using glycerol monolinoleate.
Cheng Yu-Ling (Cupertino CA) Gale Robert M. (Los Altos CA) Sugihara Edna (Mountain View CA) Sanders Harold F. (San Jose CA), Skin permeation enhancer compositions using sucrose esters.
Chiang Chia-Ming (Foster City CA) Cleary Gary W. (San Mateo CA), Skin permeation enhancer compositions, and methods and transdermal systems associated therewith.
Sylvia Rossi-Montero ; Juan Mantelle ; David Kanios ; David Houze, Solubility enhancement of drugs in transdermal drug delivery systems and methods of use.
Miranda Jesus (Miami FL) Sablotsky Steven (Miami FL), Solubility parameter based drug delivery system and method for altering drug saturation concentration.
Miranda Jesus (Miami FL) Sablotsky Steven (Miami FL), Solubility parameter based drug delivery system and method for altering drug saturation concentration.
Enscore David J. (Sunnyvale CA) Campbell Patricia S. (Palo Alto CA) Osborne James L. (Mountain View CA) Smart Melinda K. (Sunnyvale CA) Yum Su I. (Los Altos CA), Subsaturated transdermal therapeutic system having improved release characteristics.
Enscore David J. (Sunnyvale CA) Campbell Patricia S. (Palo Alto CA) Osborne James L. (Mountain View CA) Smart Melinda K. (Sunnyvale CA) Yum Su I. (Los Altos CA), Subsaturated transdermal therapeutic system having improved release characteristics.
Enscore David J. (Sunnyvale CA) Campbell Patricia S. (Palo Alto CA) Osborne James L. (Mountain View CA) Smart Melinda K. (Sunnyvale CA) Yum Su I. (Los Altos CA), Subsaturated transdermal therapeutic system having improved release characteristics.
Chandrasekaran Santosh K. (Palo Alto CA) Darda Siegfried (Ingelheim am Rhein CA DEX) Michaels Alan S. (Atherton CA) Cleary Gary W. (Palo Alto CA), Therapeutic system for administering clonidine transdermally.
Chien Yie W. (North Brunswick NJ) Chiang Chin-Chih (Piscataway NJ) Tojo Kabuji (Highland Park NJ), Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration.
Lee Hai Bang (Taejeon KRX) Shin Bung Chul (Taejeon KRX), Transdermal administration method of protein or peptide drug and its administration device thereof.
Gale Robert M. (Los Altos CA) Goetz Victor (Palo Alto CA) Lee Eun S. (Redwood City CA) Taskovich Lina T. (Palo Alto CA) Yum Su I. (Los Altos CA), Transdermal administration of fentanyl and device therefor.
Gale Robert M. (Los Altos CA) Enscore David J. (Sunnyvale CA) Nedberge Diane E. (Los Altos CA) Nelson Melinda (Sunnyvale CA) Cheng Yu-Ling (Cupertino CA) Libicki Shari B. (Palo Alto CA), Transdermal administration of progesterone, estradiol esters, and mixtures thereof.
Nedberge Diane E. (Los Altos CA) Campbell Patricia S. (Palo Alto CA) Gale Robert M. (Los Altos CA) Yum Su I. (Los Altos CA), Transdermal contraceptive formulations.
Kochinke Frank (San Jose CA) Pfister William R. (Union City CA) Louie Jenny (Fremont CA) Arenson Dan (Escondido CA), Transdermal delivery systems for the modulated administration of drugs.
Song, Jin Deog; Park, Chul Min; Choi, Young Kwon; Lee, Heon Han; Shim, Yong Ho; Yoon, Hye Jeong, Transdermal drug delivery system for anti-inflammatory analgesic agent comprising diclofenac diethylammonium salt, and the manufacturing method thereof.
Nelson Gregory R. (St. Paul MN) Zerbe Horst-Georg (St. Paul MN) Moore Cheryl L. (St. Paul MN) Wick Steven M. (St. Paul MN), Transdermal estradiol delivery system.
Jona Janan ; Audett Jay ; Singh Noel, Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen.
Jona Janan ; Audett Jay ; Singh Noel, Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen.
Chen Yu-Ling (Cupertino CA) Chun Leslie L. (Palo Alto CA) Enscore David J. (Sunnyvale CA), Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine.
Quan Danyi ; Deshpanday Ninad A. ; Venkateshwaran Srinivasan ; Ebert Charles D., Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
Sharma Kuldeepak (Mountain View CA) Roos Eric J. (Menlo Park CA) Dunbar Darth M. (San Mateo CA), Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.